Boston University
room765 Commonwealth Ave
arrow_backSee all Organisations

  • Total Commitments

    $0

  • Total Disbursements

    $0

  • Total Expenditures

    $18.39 M

  • Total Incoming Funds

    $0

  • BB100 - A Humanized Monoclonal Antibody Targeting multi-Drug Resistant Escherichia coli ST131-O25b IATI

    • date_range Jul 01, 2019 - Sep 30, 2020
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Procarta - PRO-202 IATI

    • date_range Jul 01, 2019
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Vaxcyte - Safe Universal Carbohydrate Conjugate GAS Vaccine IATI

    • date_range Jun 01, 2019 - Mar 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • BioVersys - Anti-Virulence Adjunctive Therapy Against Resistant Staphylococus aureus (AVATAR-SA) IATI

    • date_range Nov 01, 2019 - Apr 30, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Amicrobe - Amicidin-Beta IATI

    • date_range Mar 01, 2019
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Lytica - Stapled Antimicrobial Peptides for Gram-negative Infections IATI

    • date_range Oct 01, 2019 - Jun 30, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Vaxdyn - KAPAVAX IATI

    • date_range Jun 01, 2019 - Nov 30, 2020
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • GangaGen Engineered therapeutic protein antibiotics targeting drug-resistant Enterobacteriaceae IATI

    • date_range Aug 01, 2020 - Jul 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Lumen - Oral anti-microbial immunotherapy against ETEC and campylobacter IATI

    • date_range Aug 01, 2020 - Mar 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • HZI CIR - Small molecule inhibitors of α-hemolysin for the treatment of S. aureus lung infections IATI

    • date_range Oct 01, 2020 - Sep 30, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Jenner - dmGC_0817560 IATI

    • date_range Jan 01, 2021 - Jul 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • GVGH-Sal: 06CARB-X968; A combination vaccine for sustainable prevention of invasive Salmonelloses in sub-Saharan Africa IATI

    • date_range Oct 01, 2020 - Jul 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • GVGH-GAS: Group A Streptococcus vaccine (06CARB-X0955) IATI

    • date_range Oct 01, 2020 - Jul 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Phico: Pre-clinical and clinical development of intravenous Pseudomonas aeruginosa SASPject technology IATI

    • date_range Feb 01, 2021 - Jul 31, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Cross-Project Initiative IATI

    • date_range Apr 01, 2021
    • autorenew Implementation (Status)
    Total Budget 0 USD

  • Queensland ODA - OctapeptinX (OPX) for XDR Gram-negative infections IATI

    IATI Identifier: US-EIN-04-2103547-Queensland
    • date_range Jul 01, 2020 - Mar 31, 2021
    • autorenew Pipeline/identification (Status)
    Total Budget 1,592,673 USD

  • Integrated Biotherapeutics -IBT V-02 IATI

    IATI Identifier: US-EIN-04-2103547-Integrated Biotherapeutics
    • date_range Sep 05, 2019 - Sep 09, 2019
    • autorenew Implementation (Status)
    Total Budget 3,112,689 USD